摘要
目的分析重组人干扰素α1b雾化吸入联合布地奈德对反复上呼吸道感染(RURTI)患儿的治疗效果。方法选取2022年6月至2023年6月我院收治的90例RURTI患儿,随机分为联合组(n=45)和单一组(n=45),单一组予以匹多莫德治疗,联合组予以重组人干扰素α1b雾化吸入联合布地奈德治疗。对比两组的临床疗效、症状消失时间及不良反应。结果联合组总有效率为93.33%,高于单一组的75.56%(P<0.05)。联合组发热、咽喉肿痛、咳嗽、肺啰音消失时间短于单一组(P<0.05)。两组的不良反应发生率比较无统计学差异(P>0.05)。结论重组人干扰素α1b雾化吸入联合布地奈德治疗RURTI患儿可提高临床疗效,缩短发热、咽喉肿痛、咳嗽、肺啰音消失时间,安全性良好。
Objective To analyze the treatment effect of recombinant human interferonαlb nebulized inhalation combined with budesonide on children with recurrent upper respiratory tract infections(RURTI).Methods 90 RURTI children admitted to our hospital from June 2022 to June 2023 were selected and randomly divided into combined group(n=45)and single group(n=45).The single group was treated with pidotimod,while the combined group was treated with recombinant human interferonαlb nebulized inhalation combined with budesonide.The clinical efficacy,symptom disappearance time and adverse reactions were compared between the two groups.Results The total effective rate of the combined group was 93.33%,higher than 75.56%of the single group(P<0.05).The disappearance time of fever,sore throat,cough,and lung rales in the combined group was shorter than that in the single group(P<0.05).No statistical difference was found in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Recombinant human interferonαlb nebulized inhalation combined with budesonide in the treatment of RURTI children can improve the clinical efficacy,and shorten the disappearance time of fever,sore throat,cough,and lung rales,with good safety.
作者
仝玲
古健鹏
TONG Ling;GU Jianpeng(Department of Pediatrics,Tanghe County People's Hospital,Nanyang 473400,China;Zhengzhou University School of Medicine,Zhengzhou 450052,China)
出处
《临床医学工程》
2024年第7期845-846,共2页
Clinical Medicine & Engineering
关键词
反复上呼吸道感染
重组人干扰素Α1B
布地奈德
Recurrent upper respiratory tract infection
Recombinant human interferonαlb
Budesonide
